• 1
    Tallman MS,Gilliland DG,Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 11541163.
  • 2
    Grimwade D,Walker H,Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML10 trial. Blood 1998; 92: 23222333.
  • 3
    Grimwade D,Walker H,Harrison G, et al. The predictive value of hierarchical classification in older aults with AML: Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 13121320.
  • 4
    Gupta V,Chun K,Yi Q-L, et al. Disease biology rather than age is the most important determinant of survival of patients ≥ age 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 20822090.
  • 5
    Lowenberg B,Suciu S,Archimbaud E, et al. Mitoxantrone vs. daunorubicin in induction-consolidation therapy: Final report of the leukemia cooperative group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon group randomized Phase III study AML-9. J Clin Oncol 1998; 16: 872881.
  • 6
    Fröhling S,Schlenk RF,Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002; 100: 43724380.
  • 7
    Wheatley K,Burnett AK,Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the AML MRC 10 trial. Br J Haematol 1999; 107: 6979.
  • 8
    Rowe JM,Kim HT,Cassileth PA, et al. Time to complete remission is not a significant prognostic factor in AML: A report on 1959 consecutive patients registered to 6 studies of the Eastern Cooperative Oncology Group (ECOG). Blood 2004; 104: 246a.
  • 9
    Rocha V,Labopin M,Sanz G, et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. New Engl J Med 2004; 351: 22762285.
  • 10
    Mollee P,Gupta V,Song K, et al. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. Bone Marrow Transplant 2004; 33: 12011208.
  • 11
    Levis M,Smith BD,Beran M, et al. A randomized open label study of lestaurtinib (CEP-701) an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition. Blood 2005; 106: 121a.
  • 12
    Lancet J,Gojo I,Gotlib J, et al. Tipifarnib (Zarnestra) in previously treated poor risk AML and MDS: Interim results of a Phase II trial. Blood 2003; 102: 176a.
  • 13
    Kosugi H,Towatari M,Halano S, et al. Histone deacetylase inhibitors are the potent inducer/enhancers of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy. Leukemia 1999; 13: 13161324.
  • 14
    Marcucci G,Byrd J,Dai G, et al. Phase I and pharmacokinetic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425432.
  • 15
    Feldman EJ,Brandwein J,Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy versus chemotherapy alone in patients with refractory or first relapsed acute myeloid leukemia. J Clin Oncol 2005; 23: 41104116.
  • 16
    Slovak ML,Kopecky KJ,Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 40754083.